Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.
This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.
Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.
Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.
Theravance Biopharma (TBPH) has announced significant strategic moves, including increasing its capital return program from $250 million to $325 million. As of February 27, 2023, approximately $170 million remains in this program. The company reported $19.5 million in YUPELRI® sales for Q4 2022, a 27% year-over-year increase, marking its strongest quarter. Additionally, Theravance will discontinue research investments and reduce headcount by 17% to focus resources on the ampreloxetine Phase 3 study. The company reaffirmed its guidance for non-GAAP profitability in the second half of 2023.
Irenic Capital Management, a major shareholder of Theravance Biopharma (NASDAQ: TBPH), criticized the company's leadership and called for strategic changes. Since its separation in 2014, Theravance's total shareholder return has plummeted by -50%, reflecting a significant discount in its market value. Irenic proposed actions such as returning $300 million in excess cash to shareholders, reducing operational costs, and improving governance by appointing a shareholder representative. They estimate that adopting these measures could unlock nearly $21 per share in value, substantially higher than its current trading price of $9.87.
Theravance Biopharma (TBPH) will announce its fourth quarter and full-year 2022 financial results on February 27, 2023, after market close. A conference call and webcast are scheduled for 5:00 PM ET on the same day, allowing investors to gain insights into the company's performance. Interested parties can participate by pre-registering online. The company is known for its FDA-approved drug, YUPELRI, aimed at treating COPD and continues to focus on developing new therapies for unmet medical needs.
Theravance Biopharma (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 8:00 am ET. The event can be accessed via a webcast on Theravance.com in the Investors section. A replay will be available for 30 days post-event. Theravance Biopharma is committed to delivering Medicines that Make a Difference and is known for its FDA-approved YUPELRI® inhalation solution for COPD. The company focuses on addressing significant unmet patient needs through its innovative pipeline.
Theravance Biopharma (TBPH) announced significant 2022 achievements and 2023 objectives. Key highlights include strategic advances in YUPELRI sales growth, with all-time high net sales reported in Q2 and Q3. The company initiated the Phase 3 CYPRESS study for ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) planned for Q1 2023, alongside a $250 million capital return program. With FDA discussions and a $1.1 billion royalty sale, Theravance aims for Non-GAAP profitability by 2H 2023, reinforcing its commitment to delivering impactful medicines.
On November 22, 2022, Theravance Biopharma (NASDAQ: TBPH) announced the final results of its Dutch auction tender offer, which aimed to purchase up to $95 million of its ordinary shares. The offer expired on November 17, 2022, with a total of 115,967 shares tendered and accepted at $10.50 each, totaling approximately $1.2 million. This amount represents about 0.2% of the shares outstanding. The company plans to use the unused funds for an open market share repurchase program expected to commence after the tender offer's completion.
Theravance Biopharma (NASDAQ: TBPH) announced the preliminary results of its Dutch auction tender offer, intending to purchase up to $95 million of ordinary shares. The offer expired on November 17, 2022, with 115,967 Shares tendered. The company plans to purchase these shares at $10.50 each, totaling approximately $1.2 million. This represents about 0.2% of the total shares outstanding. Additionally, the unused portion of the offer will fund an open market share repurchase plan expected to begin after the tender offer concludes.
Theravance Biopharma (NASDAQ: TBPH) reported a record quarter for YUPELRI® (revefenacin) with Q3 2022 net sales reaching $18.7 million, a 35% increase year-over-year. The company completed a significant transaction selling TRELEGY ELLIPTA royalty rights to Royalty Pharma for $1.1 billion in upfront cash and potential milestones. With a strong cash position of $487 million, Theravance is debt-free and initiated a $250 million capital return program. R&D expenses decreased significantly to $9.9 million, while total revenue for Q3 was $12.5 million.
Theravance Biopharma (NASDAQ: TBPH) announced promising Phase 3 results for its investigational drug, Ampreloxetine, targeting neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Data presented at the 33rd International Symposium on the Autonomic Nervous System shows significant symptom improvement across multiple scales compared to placebo. Ampreloxetine demonstrated a similar safety profile to placebo, with no significant adverse effects. The company plans to initiate a new registrational Phase 3 study in early 2023, aiming to file for NDA with the FDA.
Theravance Biopharma, Inc. (NASDAQ: TBPH) will announce its third quarter 2022 financial results and provide a business update after market close on November 7, 2022. A conference call and webcast will follow at 5:00 pm ET. The company focuses on delivering Medicines that Make a Difference and has developed the FDA-approved YUPELRI inhalation solution for COPD patients. Investors can listen to the live call via Theravance's website and access a replay for 30 days post-event.
FAQ
What is the current stock price of Theravance Bioph (TBPH)?
What is the market cap of Theravance Bioph (TBPH)?
